MET and cancer: In addition to its effects on E‐cadherin and MMPs, it has been found that c‐MET regulates EMT in cancer cells through the activation of hBνR (human biliverdin reductase), an ERK nuclear transporter required for MAPK signaling (Lerner‐Marmarosh et al, 2008; Liu et al, 2017).